滤泡性淋巴瘤预后因素评估及个体化危险分层研究进展

Research progress of prognostic factors evaluation and individualized risk stratification in follicular lymphoma

滤泡性淋巴瘤（follicular lymphoma,FL）是最常见的惰性非霍奇金淋巴瘤（NHL）。在西方国家,FL占所有NHL的35%。在美国,FL的发病率约为3/100 000,欧洲人群发病率约2/100 000。FL的中位发病年龄为65岁,5%-10%的患者发病年龄〈40岁;30%-40%的患者初诊时为疾病的早期阶段，而大部分患者初诊时病变即处于进展期。

Follicular lymphoma（FL）is a common and indolent lymphoma.The recently studies show that FL displays heterogeneity for clinical process and biological prognostic biomarkers.A large class FL patient is asymptomatic with indolent course which are vulnerable to the toxic chemo-therapies.However,a subset of FL develop chemo-resistance and undergo a transformation to aggressive lymphoma.These subtypes are needed for new therapies and alternative approaches.Following new biomarkers had been discovered,previous clinical prognostic indices for FL become limited.In this review,we introduce the clinical prognostic index in FL and novel prognostic markers for evaluating poor risk.A useful incorporation both clinical and molecular determinants for the risk stratification of FL will help to identify high-risk FL at diagnosis and choose rational targeted therapies.